Hospital

The new drug application's submission is supported by data from the phase 3 clinical studies SynAIRgy and LunAIRo.

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, discussed the patient selection, standardized workflows, toxicity management, payer coordination, and caregiver education needed to safely move bispecific step-up dosing into the outpatient setting.

In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, outlines the essential teams, SOPs, financial planning, and safety protocols community oncology practices need to launch outpatient CAR T-cell therapy successfully.

In an interview with Pharmacy Times, Cherise Steib, PharmD, HDDP, discussed patient selection, caregiver requirements, cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and the American Oncology Network’s approach to building an outpatient bispecific therapy program.

In an interview with Pharmacy Times, Steib explains how structured monitoring, patient education, emergency protocols, and pharmacist involvement support the safe delivery of outpatient bispecific therapy.

Cherise Steib, PharmD, HDDP, discusses how bispecific therapies expand treatment options and the factors that determine whether patients are appropriate candidates for outpatient administration.

Some commonly used treatments for chronic low back pain may offer limited benefit while increasing risks, underscoring the need for pharmacists to support evidence-based, patient-centered care.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, led a Pharmacy Times Clinical Forum on optimizing the management of patients with heart failure across practice settings.

New PET imaging data show reduced dopamine nerve terminal density in patients with long COVID, correlating with fatigue, motor slowing, and memory problems.

In an interview with Pharmacy Times, Maksour explained how payer restrictions on prophylactic tocilizumab and the need for intensive patient and caregiver education can influence the safety and feasibility of outpatient bispecific therapy.

AI functions as a supportive layer that improves efficiency while preserving the pharmacist’s central role in therapeutic decision-making.

A panel of pharmacists and nurse practitioners discussed how interdisciplinary diabetes teams divide technology education, medication management, and follow-up care.

Pharmacists proactively identify red flags for early detection, navigate complex insurance and access barriers for high-cost disease-modifying therapies, and serve as educators across settings.

Prepare your pharmacy for flu season with updated vaccine formulations, screening, staffing, ordering, cold-chain controls, billing workflows, and patient outreach to boost vaccination uptake.

Outpatient BiTE therapy for multiple myeloma may be safely supported in community oncology settings through careful patient selection, pharmacist-led coordination, home monitoring, caregiver education, and standardized protocols for managing CRS and ICANS.

Explore emerging flu antivirals, from season-long CD388 prevention to single-dose therapies, designed to beat current treatment limits.

If approved, AXS-12 would be a potentially valuable new option for a symptom that significantly impairs the daily functioning of those with narcolepsy.

In an interview with Pharmacy Times, Nicole McMullin, regional clinical pharmacist at American Oncology Network, discussed AON’s development of an all-outpatient approach to step-up dosing for bispecific T-cell engager therapy in multiple myeloma.

An expert discusses a JAMA study that shows who depends on the MMRV combination vaccine and how policy shifts may widen gaps—plus how pharmacists keep children on schedule.

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, associate director of pharmacy services at American Oncology Network, discusses the growing use of outpatient step-up dosing for bispecific T-cell engager therapies and the operational challenges clinics must address to safely implement these programs.

Future research should evaluate larger multicenter experiences and assess if pharmacist-supported workflows are associated with treatment persistence, safety monitoring adherence, and clinical outcomes.

TV-44749 is a subcutaneous long-acting injectable form of olanzapine that is effective in schizophrenia while avoiding risks seen with the intramuscular formulation.

Pharmacist-led pathways, multimodal analgesia, and patient-centered opioid stewardship may help improve acute pain management while balancing opioid safety, adequate pain relief, and access to emerging nonopioid options.

Case counts will likely continue to rise as reporting catches up with the incubation lag.

Selpercatinib received approval for adults and children 2 years and older with previously treated or treatment-refractory RET fusion–positive solid tumors.

In an interview with Pharmacy Times, Brandon Kasberg, PharmD, discusses how pharmacists can help individualize multimodal acute pain regimens, reduce unnecessary opioid exposure, and support safer transitions from inpatient or postoperative care to the outpatient setting.

This FAQ breaks down which drugs are covered by the program, who qualifies, how to process claims correctly, and what pharmacists need to know to counsel patients through this landmark shift in obesity drug access.

Emerging data on psychedelics demonstrate efficacy in preventing cluster headaches.